Delivery Order SPE2DB20D3505-SPE2DB25FV0G2
- Not listed
- The Defense Logistics Agency awarded a $2,697.75 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections. The contract is a firm fixed-price delivery order with no set-aside designation, reflecting AmerisourceBergen's ability to compete successfully in open federal procurement. Performance will be completed by July 21, 2025, with fulfillment occurring at the contractor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a ceiling value of $1,525.20. This firm fixed-price delivery order is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a non-set-aside competitive procurement under the company's existing Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,205.08 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pen injections on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The delivery...
- The Defense Logistics Agency awarded a $35,358.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injections. The contract, designated as a non-set-aside competitive award, calls for completion by August 18, 2025, with performance at the contractor's location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $13,457.64 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of July 28, 2025, and performance to be executed at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $7,625.80 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This is a firm fixed price, non-set-aside contract with a completion date of August 15, 2025, to be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $11,285.76 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injectors. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 31, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order contract valued at $3,813.85 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This competitive, firm fixed-price delivery order is set to be completed by July 28, 2025, with performance occurring at the company's corporate headquarters in Conshohocken, Pennsylvania. The award represents a child order issued under a larger contract vehicle supporting the federal medical...
- The Defense Logistics Agency awarded a $3,558.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 2.5 mg/0.5 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections with a ceiling value of $5,860.42. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents a competitive award with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FV0G2Delivery Order
The Defense Logistics Agency awarded a $3,266.90 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections. The contract, which is not set-aside and was competitively awarded, has a performance location in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order operates under a firm fixed price structure and represents a child contract issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal medical procurement vendor specializing in pharmaceutical products and medical supplies for military and veteran healthcare systems. The company's extensive federal contract portfolio encompasses a wide range of medications across multiple therapeutic domains, including diabetes treatments, neurological medications, pain management pharmaceuticals, and specialized medical devices. This specific delivery order for Zepbound exemplifies the company's role in supplying brand-name pharmaceutical products to support Defense Health Agency and other federal healthcare programs through the comprehensive DLA Pharmaceutical Prime Vendor Global Program framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 7/22/25 |